100.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Axsome: Some Recent Setbacks, Some Recent Wins — Still A Buy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Trading Down 5.6%Time to Sell? - MarketBeat
Why Axsome Therapeutics Inc. stock is on top investor watchlistsSuperior stock selection - jammulinksnews.com
What analysts say about Axsome Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
Axsome Therapeutics Inc. Stock Analysis and ForecastRapid growth trajectories - PrintWeekIndia
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
New York State Common Retirement Fund Has $3.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. stock overhyped or has real potentialUnstoppable trading performance - jammulinksnews.com
How high can Axsome Therapeutics Inc. stock price go in 2025Breakthrough investment results - jammulinksnews.com
How To Trade (AXSM) - news.stocktradersdaily.com
Y Intercept Hong Kong Ltd Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is This Stock a Buy After Soaring by 20% in 1 Day? - AOL.com
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN
William Blair Issues Positive Forecast for AXSM Earnings - MarketBeat
Legato Capital Management LLC Buys New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Increased by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating - AInvest
Optimistic Outlook for Axsome Therapeutics: Promising Pipeline and Potential Sales Growth Drive Buy Rating - TipRanks
Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq
What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com
Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Mizuho reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com South Africa
Axsome Therapeutics: Promising Growth Driven by Robust Pipeline and Strategic Fit - TipRanks
Lindbrook Capital LLC Sells 14,103 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Rings the Opening Bell - Nasdaq
Axsome Therapeutics hosts frontiers in Brain Health R&D Day - TipRanks
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - Lelezard
Axsome Therapeutics: A CNS Pipeline with High-Impact Catalysts for Long-Term Growth - AInvest
Axsome Therapeutics Hosts R&D Day to Present Comprehensive Data on CNS Pipeline Targeting Alzheimer’s Disease, Depression, Narcolepsy, Fibromyalgia, ADHD, and Smoking Cessation - Nasdaq
Axsome Reveals New Phase 3 Data for 6 Major Brain Disorders: Expert Panel Discusses Breakthrough Treatments - Stock Titan
Axsome Celebrates New CNS Drug Launch with NASDAQ Bell Ringing, Unveils Brain Health Pipeline - Stock Titan
Bank of New York Mellon Corp Has $15.28 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Issues Negative Outlook for AXSM Earnings - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Mizuho reiterates Outperform rating on Axsome Therapeutics stock ahead of R&D Day - Investing.com Australia
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):